The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.

M A Khamashta; I N Bruce; C Gordon; D A Isenberg; O Ateka-Barrutia; M Gayed; C Donatti; A-L Guillermin; J Foo; A Perna

doi:10.1177/0961203313517407

The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.

M A Khamashta, I N Bruce, C Gordon, D A Isenberg, O Ateka-Barrutia, M Gayed, C Donatti, A-L Guillermin, J Foo, A Perna

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVES: The aim of the Systemic LUpus Erythematosus Cost of Care In Europe (LUCIE) study was to evaluate the annual direct medical costs of managing adults with active autoantibody-positive disease on medication for SLE in secondary care. This paper presents the UK analyses only. METHODS: A cost-of-illness study was conducted from the perspective of the National Health Service. Health resource utilization data were retrieved over a two-year period from four centres in England and unit cost data were taken from published sources. RESULTS: At baseline, 86 patients were included, 38 (44.2%) had severe SLE and 48 (55.8%) had non-severe SLE. The mean (SD) SELENA-SLEDAI score was 7.7 (5.7). The mean (SD) annual direct medical cost of was estimated at £3231 (£2333) per patient and was 2.2 times higher in patients with severe SLE compared with patients with non-severe SLE (p

Original language	English
Journal	Lupus
Volume	23
Issue number	3
DOIs	https://doi.org/10.1177/0961203313517407
Publication status	Published - Mar 2014

Keywords

Lupus flare
antinuclear antibody
direct cost
health care resources
management costs

Access to Document

10.1177/0961203313517407

Cite this

@article{ec527e84b0684c90a18f004f97f6c471,

title = "The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.",

abstract = "OBJECTIVES: The aim of the Systemic LUpus Erythematosus Cost of Care In Europe (LUCIE) study was to evaluate the annual direct medical costs of managing adults with active autoantibody-positive disease on medication for SLE in secondary care. This paper presents the UK analyses only. METHODS: A cost-of-illness study was conducted from the perspective of the National Health Service. Health resource utilization data were retrieved over a two-year period from four centres in England and unit cost data were taken from published sources. RESULTS: At baseline, 86 patients were included, 38 (44.2%) had severe SLE and 48 (55.8%) had non-severe SLE. The mean (SD) SELENA-SLEDAI score was 7.7 (5.7). The mean (SD) annual direct medical cost of was estimated at £3231 (£2333) per patient and was 2.2 times higher in patients with severe SLE compared with patients with non-severe SLE (p ",

keywords = "Lupus flare, antinuclear antibody, direct cost, health care resources, management costs",

author = "Khamashta, {M A} and Bruce, {I N} and C Gordon and Isenberg, {D A} and O Ateka-Barrutia and M Gayed and C Donatti and A-L Guillermin and J Foo and A Perna",

note = "NF-SI-0512-10105, Department of Health, United Kingdom",

year = "2014",

month = mar,

doi = "10.1177/0961203313517407",

language = "English",

volume = "23",

journal = "Lupus",

issn = "1477-0962",

publisher = "Sage Publications Ltd",

number = "3",

}

TY - JOUR

T1 - The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.

AU - Khamashta, M A

AU - Bruce, I N

AU - Gordon, C

AU - Isenberg, D A

AU - Ateka-Barrutia, O

AU - Gayed, M

AU - Donatti, C

AU - Guillermin, A-L

AU - Foo, J

AU - Perna, A

N1 - NF-SI-0512-10105, Department of Health, United Kingdom

PY - 2014/3

Y1 - 2014/3

N2 - OBJECTIVES: The aim of the Systemic LUpus Erythematosus Cost of Care In Europe (LUCIE) study was to evaluate the annual direct medical costs of managing adults with active autoantibody-positive disease on medication for SLE in secondary care. This paper presents the UK analyses only. METHODS: A cost-of-illness study was conducted from the perspective of the National Health Service. Health resource utilization data were retrieved over a two-year period from four centres in England and unit cost data were taken from published sources. RESULTS: At baseline, 86 patients were included, 38 (44.2%) had severe SLE and 48 (55.8%) had non-severe SLE. The mean (SD) SELENA-SLEDAI score was 7.7 (5.7). The mean (SD) annual direct medical cost of was estimated at £3231 (£2333) per patient and was 2.2 times higher in patients with severe SLE compared with patients with non-severe SLE (p

AB - OBJECTIVES: The aim of the Systemic LUpus Erythematosus Cost of Care In Europe (LUCIE) study was to evaluate the annual direct medical costs of managing adults with active autoantibody-positive disease on medication for SLE in secondary care. This paper presents the UK analyses only. METHODS: A cost-of-illness study was conducted from the perspective of the National Health Service. Health resource utilization data were retrieved over a two-year period from four centres in England and unit cost data were taken from published sources. RESULTS: At baseline, 86 patients were included, 38 (44.2%) had severe SLE and 48 (55.8%) had non-severe SLE. The mean (SD) SELENA-SLEDAI score was 7.7 (5.7). The mean (SD) annual direct medical cost of was estimated at £3231 (£2333) per patient and was 2.2 times higher in patients with severe SLE compared with patients with non-severe SLE (p

KW - Lupus flare

KW - antinuclear antibody

KW - direct cost

KW - health care resources

KW - management costs

U2 - 10.1177/0961203313517407

DO - 10.1177/0961203313517407

M3 - Article

C2 - 24356612

SN - 1477-0962

VL - 23

JO - Lupus

JF - Lupus

IS - 3

ER -

The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.

Abstract

Keywords

Access to Document

Fingerprint

Cite this